A large-scale synthesis of existing studies concludes that commonly prescribed antidepressant medications used during pregnancy are not clearly associated with higher risks of neurodevelopmental disorders such as autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in offspring once underlying factors are taken into account.
The investigators combined results from 37 prior studies, encompassing nearly 650,000 pregnancies in which antidepressants were used and almost 25 million pregnancies without exposure. On crude comparison, children born to mothers who took antidepressants showed a slightly higher rate of diagnoses for autism and ADHD. However, researchers report that these apparent associations were markedly attenuated - and in many cases no longer statistically significant - after analyses adjusted for maternal mental health status, family history, genetic contributions and other variables that can influence neurodevelopmental outcomes. The findings are reported in The Lancet Psychiatry.
Study lead Dr. Wing-Chung Chang of the University of Hong Kong summarized the results in a statement: "Our study provides reassuring evidence that commonly used antidepressants do not increase the risk of neurodevelopmental disorders such as autism and attention deficit hyperactivity disorder in children."
Experts not involved in the research cautioned that simple comparisons can be misleading. As Dr. James Walker, professor emeritus of obstetrics and gynecology at the University of Leeds, noted: "If you simply compare children whose mothers took antidepressants with children whose mothers did not, you may find a difference. But that does not mean the medicine caused the difference."
The research team examined patterns that help distinguish medication effects from shared familial or pre-existing factors. Higher apparent risks were observed in children whose fathers were using antidepressants while their partners were pregnant, and in children whose mothers had used antidepressants prior to pregnancy but not during gestation. Because a father’s medication cannot directly expose the fetus in utero, this pattern supports the interpretation that shared family characteristics - whether genetic, behavioral or environmental - may underlie the observed associations rather than direct drug effects.
Additional analyses did not show a dose-response relationship; higher doses of antidepressants were not linked to increased risk in offspring. That absence of a clear dose effect further weakens a causal interpretation tying prenatal antidepressant exposure to later neurodevelopmental diagnoses.
The authors report one exception among women with pre-existing mental health disorders: the older tricyclic antidepressants amitriptyline and nortriptyline were associated with increased risks of ADHD and autism in children of those patients. These medications are generally prescribed when other treatments have not been effective, which suggests that the association may reflect more severe or treatment-resistant maternal illness rather than a direct medication effect.
The researchers offer clinical context for treatment choices. For pregnant women experiencing mild depression, nonpharmacological interventions such as psychotherapy could be preferred. At the same time, the authors advise that antidepressants should not be withheld during pregnancy solely on the basis of inconsistent or potentially confounded reports of neurodevelopmental risk. They emphasize that abrupt discontinuation of medication may worsen maternal depression, and worsening maternal mental illness can have adverse consequences for both mother and child.
Clinicians and public health experts highlight the harms of undertreated maternal psychiatric illness. Dr. Anita Banerjee, an obstetrician at King’s College London who was not involved in the study, pointed out that mental health disorders are a leading cause of maternal mortality in the year following childbirth in the United Kingdom, underlining that insufficient treatment of maternal mental illness carries substantial risks.
The study also touches on the public debate around neurodevelopmental risks. It notes that assertions claiming particular antidepressants cause fetal harm have been advanced without supporting evidence by some public figures, and situates the new findings as counter to those claims. The investigators underscore that the underlying causes of autism remain unclear and that scientific speculation persists that key neurological patterns may originate in utero during fetal brain development.
Overall, the pooled evidence from this large body of research provides reassurance that commonly used antidepressant medications are unlikely to be a major independent driver of ASD or ADHD risk in children when analyses account for maternal mental health, family history and other confounders. The study reinforces the importance of individualized clinical decision-making that balances the risks of undertreated maternal illness against the limited and potentially confounded evidence for direct medication-related neurodevelopmental harm.